Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...

Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Kura Oncology in a research report issued on ...

Kura Oncology (NASDAQ:KURA – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Even the best stock pickers will make plenty of bad investments. Anyone who held Kura Oncology, Inc. (NASDAQ:KURA) over the last year knows what a loser feels like. The share price is down a hefty 64% ...

SAN DIEGO — SAN DIEGO — Kura Oncology Inc. (KURA) on Wednesday reported a loss of $19.2 million in its fourth quarter. The San Diego-based company said it had a loss of 22 cents per share. The results ...

Kura Oncology, Inc. announced that its President and CEO, Troy Wilson, Ph.D., J.D., will participate in three upcoming investor conferences: the TD Cowen Health Care Conference on March 4, the ...

Kura Sushi USA, Inc. engages in the operation of technology-enabled Japanese restaurant concept. It offers a distinctive dining experience by serving authentic Japanese cuisine through an engaging ...

Kura Oncology is on track to present pivotal data for NPM1-mutated relapsed/refractory AML in early 2025. This data readout is widely anticipated as a significant catalyst for the company's stock.

Kura Oncology (KURA) announced that on March 3, 2025, the Compensation Committee of the Company’s Board of Directors granted inducement awards ...